The trajectory of companies tied to Sildenafil's history presents a challenging investment landscape. While the initial success generated substantial gains, generic alternatives have significantly eroded sales . Investing in associated pharmaceutical companies now requires a careful assessment of proprietary rights , evolving healthcare trends , an